Prelude Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Prelude Therapeutics Incorporated

11/05/2021 16:49

* Prelude Therapeutics Inc  PRLD.OQ  reported a quarterly
adjusted loss of 47 cents​​ per share for the quarter ended
in March. The mean expectation of five analysts for the quarter
was for a loss of 42 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Prelude Therapeutics Inc's reported EPS for the quarter was a
loss of 47 cents​.
* The mean earnings estimate of analysts had fallen by about 1%
in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Prelude Therapeutics Inc shares had fallen by 6.1% this
quarter and lost 43.1% so far this year.
* The company reported a quarterly loss of $21.3 million.
* Wall Street's median 12-month price target for Prelude
Therapeutics Inc is $60.00 
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is 2 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 11 at 03:49 p.m. GMT.
​All figures in US dollars